Peste 280.000 de români trăiesc cu Alzheimer. Parteneriat strategic pentru depistarea timpurie a bolii în România

Over 280,000 Romanians live with Alzheimer's disease, prompting a strategic partnership between Eli Lilly and Neuroaxis to enhance early detection. Alzheimer's poses significant public health challenges in Europe, with an expected rise in cases. The partnership aims to improve patient access to innovative medical solutions and facilitate knowledge exchange among healthcare professionals. In Romania, the absence of a national dementia strategy exacerbates the situation, as many cases remain undiagnosed. The initiative focuses on reducing the time from symptom onset to diagnosis, which is crucial for effective treatment. The collaboration will also promote integrated care and the use of biomarkers for diagnosis, ultimately improving patient outcomes.